Evidence map›Paper›PMID 38724978›Full record

ArticleJournal of nanobiotechnology2024

Radiotherapy-sensitized cancer immunotherapy via cGAS-STING immune pathway by activatable nanocascade reaction.

Honglei Hu, Shuting Zheng, Chenxi He, Yinfei Zheng, Qiming Wei, Siwen Chen, Zede Wu, Yikai Xu, Bingxia Zhao, Chenggong Yan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Honglei Hu *Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Shuting Zheng *Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Chenxi HeDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Yinfei ZhengDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Qiming WeiDepartment of Invasive Interventional, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
Siwen ChenGuangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Zede WuDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Yikai XuDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. yikaixu917@gmail.com.
Bingxia ZhaoGuangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. bingxiaz@gmail.com.
Chenggong YanDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. ycgycg007@gmail.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2017A050506011Guangdong Basic and Applied Basic Research Foundation 2021A1515011882Medical Scientific Research Foundation of Guangdong Province A2018014the National Natural Science Foundation of China 81801764the National Natural Science Foundation of China 81871334the National Natural Science Foundation of China 82072056the Pearl River Talented Young Scholar Program 2017GC010282
6 · The paper itself

Abstract

Radiotherapy-induced immune activation holds great promise for optimizing cancer treatment efficacy. Here, we describe a clinically used radiosensitizer hafnium oxide (HfO

Indexed as

FerroptosisImmunotherapyManganese CompoundsMembrane ProteinsMice, Inbred BALB CNanoparticlesNucleotidyltransferasesOxidesRadiation-Sensitizing AgentsAnimalsCell Line, TumorCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDNA DamageFemaleGlucose OxidaseHumanscGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseGlucose OxidaseManganese Compoundsmanganese dioxideMembrane ProteinsNucleotidyltransferasesOxidesRadiation-Sensitizing AgentsReactive Oxygen SpeciesSting1 protein, mouseSTING ProteincGAS-STINGFerroptosisMolecular imagingRadiotherapy sensitizationTheranostics

Identifiers

PMID38724978
PMCPMC11080188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.